|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed correspondingly lower expression levels of urokinase plasminogen activator (uPA), uPA receptor, cyclooxygenase (COX)-2, and vascular endothelial growth factor (VEGF), which are important factors in cancer metastasis, in breast tumor irradiated with 30 Gy proton beam.
|
27176787 |
2016 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.
|
22986534 |
2013 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors.
|
22842551 |
2012 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemical staining and real-time PCR assays showed that miR-193b was a negative regulator of the uPA gene in primary breast tumors.
|
19701247 |
2009 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the implementation of mRNA quantification of uPA and PAI-1 in breast tumors is unable to serve as a one-to-one substitution for antigen determination by ELISA.
|
18204793 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
|
17657740 |
2007 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
|
17258797 |
2007 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
|
16685447 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
|
15646834 |
2005 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a significant reduction in BRMS1 mRNA expression in breast tumors compared with matched normal breast tissues (paired t test, P < 0.0001) and a general inverse correlation with uPA gene expression (P < 0.01).
|
15867352 |
2005 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated urokinase-type plasminogen activator (uPA) expression in breast tumors predicts poor survival.
|
16172791 |
2005 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
|
14983219 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
|
14983227 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
|
14704150 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer.
|
12743986 |
2003 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
|
12477728 |
2003 |